MedTrace Logo

Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes

NCT02106104 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2016-05-17

No results posted yet for this study

Summary

The aim of this study is to detail the (mechanisms underlying the) actions of the DPP-4 inhibitor linagliptin on the renal system in patients with type 2 diabetes mellitus.

Conditions

Interventions

DRUG

Linagliptin 5 mg QD (N=24)

Linagliptin 5 mg will be taken orally, once daily for 8 weeks

DRUG

Glimepiride 1 mg QD (N=24)

Glimepiride 1 mg will be taken orally, once daily for 8 weeks

Sponsors & Collaborators

  • Amsterdam UMC, location VUmc

    lead OTHER

Principal Investigators

  • Mark Kramer, MD PhD · Amsterdam UMC, location VUmc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02106104 on ClinicalTrials.gov